Compare GSK plc (GSK) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs abrdn Physical Palladium Shares ETF — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while abrdn Physical Palladium Shares ETF trades at $20.92 (market cap $586.03M). The key difference: GSK plc is far larger — about 156.8× abrdn Physical Palladium Shares ETF's market cap, and GSK plc pays a 3.9% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| GSK | PALL | |
|---|---|---|
Market Cap | $91.88B | $586.03M |
Volume | 7,730,529 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $61.18 | $37.18 |
52-Week Low | $43.24 | $20.30 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
PALL trades at $20.77, up 2.32% today, but technical indicators show a bearish trend with moving averages unanimously negative. The ETF faces fundamental data gaps in valuation and profitability metrics. Recent news highlights palladium's underperformance versus other precious metals, with some analysts seeing current price weakness as a buying opportunity given supply risks and industrial demand potential.
The outlook remains cautious with strong bearish technical signals offset by potential catch-up trade opportunities. Key risks include commodity price volatility and industrial demand fluctuations, while potential upside depends on palladium market dynamics reversing recent weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
